Biogen News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

11.11.21	Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening To Facilitate Identification Of Subjects For Phase 3 Ahead 3-45 Trial Presented At Clinical Trials On Alzheimer's Disease (CTAD) Co... (PR Newswire)
11.11.21	Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference (PR Newswire)
10.11.21	Eisai Presents Late-Breaker Updates On Lecanemab Clinical, Biomarker And Safety Data From Phase 2b Study Core And Open-Label Extension Across Five Years At Clinical Trials On Alzheimer's Disease (... (PR Newswire)
03.11.21	Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting (GlobeNewswire)
20.10.21	Biogen Raises FY21 Guidance - Quick Facts (RTTNews)
20.10.21	Biogen Inc. Q3 Profit Declines (RTTNews)
17.10.21	Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS (GlobeNewswire)
14.10.21	Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting (GlobeNewswire)
13.10.21	New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience (GlobeNewswire)
13.10.21	New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis (GlobeNewswire)
28.09.21	Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway (PR Newswire)
22.09.21	Biogen Considers Drastic Cost-Cutting Measures As Alzheimer Drug Disappoints (RTTNews)
21.09.21	Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience (GlobeNewswire)
20.09.21	FDA Approves Samsung Bioepis' Byooviz, A Proposed Biosimilar To Lucentis - Quick Facts (RTTNews)
20.09.21	FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna) (GlobeNewswire)
17.09.21	Biogen Announces Positive CHMP Opinion For VUMERITY - Quick Facts (RTTNews)
17.09.21	CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis (GlobeNewswire)
16.09.21	Biogen Announces Positive Results From Phase 2 Study Of Vixotrigine In Small Fiber Neuropathy (RTTNews)
16.09.21	Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy (GlobeNewswire)
15.09.21	Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam) (GlobeNewswire)
09.09.21	Biogen Admits To "Slower Than Anticipated" Launch Of Its Alzheimer's Drug (RTTNews)
30.08.21	Biotech Stocks Facing FDA Decision In September 2021 (RTTNews)
02.08.21	Biogen: Every Six-week Natalizumab Administration Provides High Level Of Efficacy In Controlling MS (RTTNews)
02.08.21	Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis (GlobeNewswire)
29.07.21	Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401) (PR Newswire)
29.07.21	Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021 (GlobeNewswire)
27.07.21	Biogen : Phase 1b Study On Alzheimer's Disease Meets Primary Objective Of Safety & Tolerability (RTTNews)
26.07.21	Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC (PR Newswire)
23.07.21	Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference (GlobeNewswire)
22.07.21	Biogen Boosts FY21 Revenue Outlook; Q2 Results Top Estimates - Quick Facts (RTTNews)
22.07.21	An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D. (GlobeNewswire)
21.07.21	Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications (PR Newswire)
13.07.21	Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis (GlobeNewswire)
08.07.21	Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease (GlobeNewswire)
08.07.21	Biogen Says FDA Approves Updated Label For Alzheimer's Drug Aduhelm Injection - Quick Facts (RTTNews)
08.07.21	FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials (GlobeNewswire)
29.06.21	Enel X Partners Biogen To Electrify Its Employee Commercial Fleet - Quick Facts (RTTNews)
29.06.21	Enel X Collaborates With Biogen To Electrify Take-home Vehicle Fleet In North America (PR Newswire)
25.06.21	Samsung Bioepis, Biogen Get Positive CHMP Opinion For Ranibizumab Biosimilar BYOOVIZ - Quick Facts (RTTNews)
25.06.21	Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™ (GlobeNewswire)
23.06.21	Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease (PR Newswire)
17.06.21	Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study (GlobeNewswire)
16.06.21	First Patient Receives Biogen's Alzheimer's Drug Aduhelm (RTTNews)
16.06.21	Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease (GlobeNewswire)
15.06.21	Sage, Biogen Announce Positive Pivotal Phase 3 Results For Zuranolone - Quick Facts (RTTNews)
15.06.21	Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder (GlobeNewswire)
14.06.21	Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia (GlobeNewswire)
10.06.21	Two FDA Committee Members Resign Over Approval Biogen's New Alzheimer's Drug (RTTNews)
10.06.21	New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy (GlobeNewswire)
07.06.21	Biogen's Aduhelm Gets FDA Approval - A New Drug For Alzheimer's In 18 Years, Priced At $56,000/Yr (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

26.11.24		Dow Jones aktuell: Dow Jones zum Handelsende in Grün
26.11.24		Zuversicht in New York: Zum Handelsende Gewinne im NASDAQ 100
26.11.24		Börse New York: Dow Jones wenig verändert
26.11.24		Starker Wochentag in New York: NASDAQ 100-Anleger greifen am Nachmittag zu
26.11.24		Starker Wochentag in New York: S&P 500 präsentiert sich fester
26.11.24		Starker Wochentag in New York: NASDAQ Composite präsentiert sich nachmittags fester
26.11.24		Optimismus in New York: S&P 500 legt am Dienstagmittag zu
26.11.24		Pluszeichen in New York: NASDAQ Composite mittags in Grün